However, because mifepristone also blocked the proliferation of ER-negative/PR-negative MDA-MB-231 breast cancer cells (Liang et al. 2003), the relevance of PR as a mediator of the antiproliferative action of mifepristone in breast cancer cells is controversial. Here, ESR1 is linked to breast carcinoma.